166 related articles for article (PubMed ID: 23034083)
1. Effect of HIV type 1 subtype on virological and immunological response to combination antiretroviral therapy: evidence for a more rapid viral suppression for subtype A than subtype B-infected Greek individuals.
Paraskevis D; Touloumi G; Bakoyannis G; Paparizos V; Lazanas M; Gargalianos P; Chryssos G; Antoniadou A; Psichogiou M; Panos G; Katsarou O; Sambatakou H; Kordossis T; Hatzakis A;
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):461-9. PubMed ID: 23034083
[TBL] [Abstract][Full Text] [Related]
2. Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy.
Chaix ML; Seng R; Frange P; Tran L; Avettand-Fenoël V; Ghosn J; Reynes J; Yazdanpanah Y; Raffi F; Goujard C; Rouzioux C; Meyer L;
Clin Infect Dis; 2013 Mar; 56(6):880-7. PubMed ID: 23223603
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 subtypes and response to combination antiretroviral therapy in Europe.
Bannister WP; Ruiz L; Loveday C; Vella S; Zilmer K; Kjaer J; Knysz B; Phillips AN; Mocroft A;
Antivir Ther; 2006; 11(6):707-15. PubMed ID: 17310815
[TBL] [Abstract][Full Text] [Related]
4. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
[TBL] [Abstract][Full Text] [Related]
5. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
6. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures.
Trotta MP; Cozzi-Lepri A; Ammassari A; Vecchiet J; Cassola G; Caramello P; Vullo V; Soscia F; Chiodera A; Ladisa N; Abeli C; Cauda R; Buonuomi AR; Antinori A; d'Arminio Monforte A;
Clin Infect Dis; 2010 Aug; 51(4):456-64. PubMed ID: 20597690
[TBL] [Abstract][Full Text] [Related]
7. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
8. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
[TBL] [Abstract][Full Text] [Related]
9. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
10. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B.
Scherrer AU; Ledergerber B; von Wyl V; Böni J; Yerly S; Klimkait T; Bürgisser P; Rauch A; Hirschel B; Cavassini M; Elzi L; Vernazza PL; Bernasconi E; Held L; Günthard HF;
Clin Infect Dis; 2011 Dec; 53(11):1143-52. PubMed ID: 21998284
[TBL] [Abstract][Full Text] [Related]
11. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
[TBL] [Abstract][Full Text] [Related]
12. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.
Hocqueloux L; Avettand-Fènoël V; Jacquot S; Prazuck T; Legac E; Mélard A; Niang M; Mille C; Le Moal G; Viard JP; Rouzioux C;
J Antimicrob Chemother; 2013 May; 68(5):1169-78. PubMed ID: 23335199
[TBL] [Abstract][Full Text] [Related]
13. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F;
HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859
[TBL] [Abstract][Full Text] [Related]
14. Rapid suppression of HIV-RNA is associated with improved control of immune activation in Mozambican adults initiating antiretroviral therapy with low CD4 counts.
Almeida JM; Letang E; Nhampossa T; Ayala E; David C; Menendez C; Gascon J; Alonso P; Naniche D
AIDS Res Hum Retroviruses; 2011 Jul; 27(7):705-11. PubMed ID: 21091388
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
16. No change in viral set point or CD4 cell decline among antiretroviral treatment-naïve, HIV-1-infected individuals enrolled in the Danish HIV Cohort Study in 1995-2010.
Helleberg M; Kronborg G; Larsen CS; Pedersen G; Pedersen C; Obel N; Gerstoft J
HIV Med; 2013 Jul; 14(6):362-9. PubMed ID: 23433434
[TBL] [Abstract][Full Text] [Related]
17. Long-term response to combination antiretroviral therapy in HIV-infected children in the Netherlands registered from 1996 to 2012.
Cohen S; Smit C; van Rossum AM; Fraaij PL; Wolfs TF; Geelen SP; Schölvinck EH; Warris A; Scherpbier HJ; Pajkrt D;
AIDS; 2013 Oct; 27(16):2567-75. PubMed ID: 23842124
[TBL] [Abstract][Full Text] [Related]
18. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
Lampe FC; Gatell JM; Staszewski S; Johnson MA; Pradier C; Gill MJ; de Lazzari E; Dauer B; Youle M; Fontas E; Krentz HB; Phillips AN
Arch Intern Med; 2006 Mar; 166(5):521-8. PubMed ID: 16534038
[TBL] [Abstract][Full Text] [Related]
19. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
Collazos J; Asensi V; Cartón JA
AIDS; 2007 Apr; 21(7):835-43. PubMed ID: 17415038
[TBL] [Abstract][Full Text] [Related]
20. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
